| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $61.7M | — | +13.8% |
| Cost of Revenue | $11.0M | — | +16.9% |
| R&D Expense | $32.0M | — | -4.4% |
| SG&A Expense | $14.3M | — | -11.4% |
| Operating Income | -$15.3M | — | +43.2% |
| Pre-tax Income | -$11.3M | — | +48.3% |
| Income Tax | $137K | — | -2.8% |
| Net Income | -$11.4M | — | +48.0% |
| EPS (Basic) | -$0.03 | — | +50.0% |
| EPS (Diluted) | -$0.03 | — | +50.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $56.1M | -11.4% | -2.1% |
| Accounts Receivable | $32.7M | -5.0% | +51.6% |
| Current Assets | $415.9M | -7.2% | -7.9% |
| Total Assets | $452.5M | -7.0% | -8.6% |
| Current Liabilities | $29.7M | -7.1% | +3.7% |
| Total Liabilities | $51.0M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $1.2M | — | +238.9% |
| Capital Expenditures | $70K | — | +150.0% |
| Investing Cash Flow | $22.7M | — | +5.4% |
| Financing Cash Flow | -$31.9M | — | -148.6% |
| Free Cash Flow | $1.2M | — | +246.2% |
| -13.3% |
| Stockholders' Equity | $401.5M | -6.9% | -7.9% |